{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Distant recurrence"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"No distant recurrence"}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"The number of participants with distant recurrence at the time of last follow-up. Distant recurrence is when cancer has spread (metastasized) to areas farther away from where the primary cancer site is.","groups":[{"description":"Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)\n\nBevacizumab: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses\n\nRadiation Therapy: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.\n\nSurgery: Surgery is performed 6-7 weeks after completion of neoadjuvant therapy.","id":"OG000","title":"Experimental: Bevacizumab, Radiation, and Surgery"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"3 years","title":"Distant Recurrence","type":"SECONDARY","unitOfMeasure":"Participants"}